Picture loading failed.

Pre-Made Odesivimab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Odesivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-390-1mg 1mg 3090
GMP-Bios-ab-390-10mg 10mg Inquiry
GMP-Bios-ab-390-100mg 100mg Inquiry
GMP-Bios-ab-390-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Odesivimab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP therapeutic antibody
INN Name Odesivimab
TargetZaire Ebolavirus GP
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesRegeneron Pharmaceuticals
Conditions ApprovedEbola virus infections
Conditions Activena
Conditions Discontinuedna
Development Techna